India Prepares for Cheaper Generic Weight-Loss Drugs After Semaglutide Patent Expiry

India's weight-loss drug market is set to expand significantly following the expiry of Novo Nordisk's semaglutide patent on March 20, 2024. At least five Indian pharmaceutical companies, including Mankind Pharma and Sun Pharma, plan to launch generic versions priced about 50% lower, around Rs 5,000 per weekly dose. This is expected to increase patient access and boost obesity treatment demand, prompting healthcare providers to expand related services. Challenges for generics include patent litigations and manufacturing complexities, while regulators have banned promotional activities to curb aggressive marketing.